VX-01
Asset
Oral inhibitor of vascular inflammatory signaling for diabetic retinopathy
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Inflammation
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2Diabetic retinopathy
Phase 2, Active not recruiting, NCT06770933, clinicaltrials.gov, 7 Oct 2026
NPDR - non proliferative diabetic retinopathy
Phase 2, Active not recruiting, NCT06770933, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Competitors3
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.